WO2005074524A3 - Modified human interferon polypeptides and their uses - Google Patents

Modified human interferon polypeptides and their uses Download PDF

Info

Publication number
WO2005074524A3
WO2005074524A3 PCT/US2005/002599 US2005002599W WO2005074524A3 WO 2005074524 A3 WO2005074524 A3 WO 2005074524A3 US 2005002599 W US2005002599 W US 2005002599W WO 2005074524 A3 WO2005074524 A3 WO 2005074524A3
Authority
WO
WIPO (PCT)
Prior art keywords
human interferon
modified human
interferon polypeptides
polypeptides
modified
Prior art date
Application number
PCT/US2005/002599
Other languages
French (fr)
Other versions
WO2005074524A2 (en
Inventor
Ho Sung Cho
Thomas Daniel
Anna-Maria Hays
Troy Wilson
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Priority to BRPI0507118-6A priority Critical patent/BRPI0507118A/en
Priority to NZ548255A priority patent/NZ548255A/en
Priority to EP05712158A priority patent/EP1718339A4/en
Priority to JP2006551473A priority patent/JP4896745B2/en
Priority to GB0617303A priority patent/GB2429207A/en
Priority to CA002553034A priority patent/CA2553034A1/en
Priority to AU2005211362A priority patent/AU2005211362B2/en
Priority to MXPA06008496A priority patent/MXPA06008496A/en
Publication of WO2005074524A2 publication Critical patent/WO2005074524A2/en
Priority to IL176596A priority patent/IL176596A0/en
Publication of WO2005074524A3 publication Critical patent/WO2005074524A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

Modified human interferon polypeptides and uses thereof are provided.
PCT/US2005/002599 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses WO2005074524A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0507118-6A BRPI0507118A (en) 2004-02-02 2005-01-28 modified human interferon polypeptides and their uses
NZ548255A NZ548255A (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses
EP05712158A EP1718339A4 (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses
JP2006551473A JP4896745B2 (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and uses thereof
GB0617303A GB2429207A (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses
CA002553034A CA2553034A1 (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses
AU2005211362A AU2005211362B2 (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses
MXPA06008496A MXPA06008496A (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses.
IL176596A IL176596A0 (en) 2004-02-02 2006-06-28 Modified human interferon polypeptides and their uses

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US54152804P 2004-02-02 2004-02-02
US60/541,528 2004-02-02
US58088504P 2004-06-18 2004-06-18
US58131404P 2004-06-18 2004-06-18
US58117504P 2004-06-18 2004-06-18
US60/581,314 2004-06-18
US60/580,885 2004-06-18
US60/581,175 2004-06-18
US63861604P 2004-12-22 2004-12-22
US60/638,616 2004-12-22

Publications (2)

Publication Number Publication Date
WO2005074524A2 WO2005074524A2 (en) 2005-08-18
WO2005074524A3 true WO2005074524A3 (en) 2007-03-29

Family

ID=34842043

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2005/002599 WO2005074524A2 (en) 2004-02-02 2005-01-28 Modified human interferon polypeptides and their uses
PCT/US2005/003537 WO2005074650A2 (en) 2004-02-02 2005-01-28 Modified human four helical bundle polypeptides and their uses
PCT/US2005/002724 WO2005074546A2 (en) 2004-02-02 2005-01-28 Modified human growth hormone polypeptides and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2005/003537 WO2005074650A2 (en) 2004-02-02 2005-01-28 Modified human four helical bundle polypeptides and their uses
PCT/US2005/002724 WO2005074546A2 (en) 2004-02-02 2005-01-28 Modified human growth hormone polypeptides and their uses

Country Status (16)

Country Link
US (15) US8119603B2 (en)
EP (4) EP1718664A4 (en)
JP (3) JP4896745B2 (en)
KR (3) KR20060130182A (en)
CN (1) CN103755800B (en)
AT (1) ATE546463T1 (en)
AU (5) AU2005211385B2 (en)
BR (3) BRPI0507118A (en)
CA (3) CA2553035A1 (en)
GB (3) GB2429207A (en)
HK (1) HK1099776A1 (en)
IL (3) IL176595A (en)
MX (3) MXPA06008496A (en)
NZ (4) NZ548255A (en)
SG (1) SG135176A1 (en)
WO (3) WO2005074524A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2343518T3 (en) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. ALFA INTERFERATED POLYPEPTIDES MODIFIED PROTEASAS RESISTANT.
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1584680A1 (en) * 2004-04-08 2005-10-12 Boehringer Ingelheim Austria GmbH Fed-batch fermentation process for the production of plasmid DNA
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
EP1771573A4 (en) * 2004-07-21 2009-02-18 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006042847A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ZA200704924B (en) * 2004-12-22 2009-04-29 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
CN103290084A (en) * 2004-12-22 2013-09-11 Ambrx公司 Method for expression and purification of recombinant human growth hormone
JP4990792B2 (en) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
MX2007007587A (en) * 2004-12-22 2007-12-11 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid.
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
JP2008541769A (en) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド Improved human interferon molecules and their use
KR20080026120A (en) * 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 Incorporation of non-naturally encoded amino acids into proteins
WO2007025988A2 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
CA2626522A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
SG170116A1 (en) * 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2632832A1 (en) * 2005-12-30 2007-07-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2009523815A (en) * 2006-01-19 2009-06-25 アンブルックス，インコーポレイテッド Unnatural amino acid polypeptides with regulated immunogenicity
US7776535B2 (en) * 2006-02-06 2010-08-17 Franklin And Marshall College Site-specific incorporation of fluorinated amino acids into proteins
PL1999259T3 (en) 2006-03-03 2015-01-30 California Inst Of Techn Site-specific incorporation of amino acids into molecules
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
CA2653748A1 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2007139997A2 (en) * 2006-05-26 2007-12-06 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Methods for site-specific pegylation
EP2040757A2 (en) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
ES2531934T3 (en) * 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Modified glycoproteins
KR100814822B1 (en) * 2006-09-05 2008-03-20 삼성에스디아이 주식회사 Light emission device, method of manufacturing the same and liquid crsytal display including the light emission device
AU2012203737B2 (en) * 2006-09-08 2014-06-19 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
CN106008699A (en) * 2006-09-08 2016-10-12 Ambrx公司 Modified human plasma polypeptide or Fc scaffolds and their uses
CN101511856B (en) 2006-09-08 2016-01-20 Ambrx公司 In vertebrate cells, suppressor trna transcribes
AU2013202770B2 (en) * 2006-09-08 2015-08-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
KR20090094812A (en) * 2006-10-18 2009-09-08 더 스크립스 리서치 인스티튜트 Genetic incorporation of unnatural amino acids into proteins in mammalian cells
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CN107501407B (en) * 2007-03-30 2022-03-18 Ambrx公司 Modified FGF-21 polypeptides and uses thereof
AU2008247815B2 (en) * 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
EP2195333A1 (en) * 2007-09-12 2010-06-16 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
US8239167B2 (en) * 2007-10-19 2012-08-07 Oracle International Corporation Gathering context information used for activation of contextual dumping
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
ES2742268T3 (en) 2007-12-26 2020-02-13 Xencor Inc Fc variants with altered FcRn binding
NZ620606A (en) * 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
AU2013202836B8 (en) * 2008-07-23 2015-07-30 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
PE20110426A1 (en) * 2008-07-23 2011-07-01 Ambrx Inc MODIFIED BOVINE G-CSF POLYPEPTIDES
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
AU2013200271B2 (en) * 2008-09-26 2014-08-28 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
CN102224238B (en) 2008-09-26 2015-06-10 Ambrx公司 Non-natural amino acid replication-dependent microorganisms and vaccines
CN107022020A (en) 2008-09-26 2017-08-08 Ambrx公司 The animal erythropoietin polypeptides and its purposes of modification
CN102245208B (en) 2008-10-14 2016-03-16 霍夫曼-拉罗奇有限公司 immunoglobulin variants and uses thereof
JP6039183B2 (en) 2008-12-23 2016-12-07 ジェネンテック， インコーポレイテッド Immunoglobulin variants with altered binding to protein A
AU2010207725B2 (en) * 2009-01-22 2015-06-11 Novo Nordisk Health Care Ag Stable growth hormone compounds
PL2417156T3 (en) 2009-04-07 2015-07-31 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102712696A (en) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 Coiled coil and/or tether containing protein complexes and uses thereof
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
CA2784793A1 (en) * 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
MX345736B (en) 2010-01-22 2017-02-14 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy.
EP2525833A2 (en) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stable growth hormone compounds
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
CA2790343A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
WO2011133751A2 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
ES2632348T3 (en) * 2010-04-28 2017-09-12 University Of Southern California Deficit of growth hormone receptors as a cause of a significant reduction in pro-aging signaling, cancer and diabetes
EP2575897A4 (en) * 2010-06-01 2016-06-01 Advanced Proteome Therapeutics Inc Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives
RS59193B1 (en) * 2010-08-17 2019-10-31 Ambrx Inc Modified relaxin polypeptides and their uses
RU2013110875A (en) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг SPECIFIC ANTIBODIES CONTAINING DISSULPHIDE-STABILIZED Fv Fragment
WO2012034061A2 (en) * 2010-09-09 2012-03-15 Traxxsson, Llc Combination methods of diagnosing cancer in a patient
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
BR112013020338A2 (en) 2011-02-28 2016-10-18 Hoffmann La Roche monovalent antigen binding protein, pharmaceutical composition, use of monovalent antigen binding protein, method for treating a patient in need of therapy, method for preparing a monovalent antigen binding protein, nucleic acid, vector and cell hostess
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
KR102004558B1 (en) 2011-07-29 2019-07-26 아벨라스 바이오사이언시즈 인코포레이티드 Selective delivery molecules and methods of use
ES2689047T3 (en) 2012-01-06 2018-11-08 3M Innovative Properties Company User application of geospatial location information of released offender
ES2617201T3 (en) 2012-01-06 2017-06-15 3M Innovative Properties Company Trend analysis of geospatial location information of released criminals
ES2614873T3 (en) 2012-01-06 2017-06-02 3M Innovative Properties Company Geospatial location information resolution center for released criminals
AU2013214698B2 (en) * 2012-02-03 2017-02-16 Antisense Therapeutics Ltd Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
CN104582736A (en) 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Incretin receptor ligand polypeptide Fc-region fusion polypeptides and conjugates with altered Fc-effector function
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
BR112014032193A2 (en) 2012-06-27 2017-06-27 Hoffmann La Roche bispecific antibody production and combination determination methods, bispecific antibody, formulation and use of bispecific antibody
LT2872534T (en) 2012-07-13 2018-10-25 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2014035364A2 (en) * 2012-08-27 2014-03-06 Empire Technology Development Llc Gelatin alkyd peptides and uses thereof
US20140161790A1 (en) 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
CA2899448C (en) 2013-01-30 2021-10-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
CN111138543A (en) 2013-03-15 2020-05-12 Xencor股份有限公司 Heterodimeric proteins
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
EP2992010B1 (en) 2013-04-29 2021-03-24 F.Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
HUE048710T2 (en) 2013-08-08 2020-08-28 Scripps Research Inst A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
EP3082847A1 (en) 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
RU2727639C2 (en) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Variants of fc-region with modified ability to bind to fcrn and with preserved ability to bind with protein a
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
EP3943607A1 (en) 2014-04-09 2022-01-26 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
PL3424534T3 (en) 2014-04-15 2021-11-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
KR101671501B1 (en) * 2014-07-24 2016-11-03 에이비온 주식회사 PEGylated Interferon-beta Variants
JP6576456B2 (en) 2014-11-06 2019-09-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Fc region variants with modified FcRn binding properties and protein A binding properties
RU2714116C2 (en) 2014-11-06 2020-02-11 Ф. Хоффманн-Ля Рош Аг VARIANTS OF Fc-DOMAIN WITH MODIFIED FcRn BINDING AND METHODS OF APPLICATION THEREOF
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
LT3223845T (en) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
EA037065B1 (en) 2014-11-26 2021-02-01 Ксенкор, Инк. Heterodimeric antibodies that bind cd3 and cd38
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN107969128A (en) 2015-04-17 2018-04-27 高山免疫科学股份有限公司 Immune modulator with adjustable affinity
US9945132B2 (en) * 2015-04-24 2018-04-17 Axia Acquisition Corporation Finisher box with blade assembly
JP6694446B2 (en) 2015-05-08 2020-05-13 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Heterodimeric antibodies that bind to CD3 and tumor antigens
CN108026172B (en) 2015-06-26 2022-04-29 赛诺菲生物技术公司 Monoclonal anti-IL-1 RACP antibodies
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists
US10874717B2 (en) 2015-07-07 2020-12-29 Burr Oak Therapeutics LLC Pegylated growth hormone antagonists
US20170101437A1 (en) * 2015-10-09 2017-04-13 Hetero Drugs Ltd. Process for purification of darbepoetin alfa
IL295756A (en) 2015-10-29 2022-10-01 Hoffmann La Roche Anti-variant fc-region antibodies and methods of use
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
UA123323C2 (en) 2016-05-02 2021-03-17 Ф. Хоффманн-Ля Рош Аг The contorsbody - a single chain target binder
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US20170349657A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
US20170349660A1 (en) 2016-06-01 2017-12-07 Xencor. Inc. Bispecific antibodies that bind cd123 and cd3
CN117024562A (en) 2016-06-20 2023-11-10 伊兰科美国公司 Pegylated porcine interferon and methods of use thereof
HUE060123T2 (en) 2016-06-24 2023-01-28 Scripps Research Inst Novel nucleoside triphosphate transporter and uses thereof
DK3347379T5 (en) 2016-08-17 2020-06-15 Compugen Ltd ANTI-TIGIT ANTIBODIES, ANTI-ENVIRONMENTAL ANTIBODIES AND COMBINATIONS THEREOF
US20190201491A1 (en) 2016-08-22 2019-07-04 Elanco Us Inc. Bovine fibroblast growth factor 21 and ketosis in dairy cattle
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019004327A (en) 2016-10-14 2019-10-14 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments.
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3565833A1 (en) 2017-01-09 2019-11-13 Torch Therapeutics Conditionally effective bispecific therapeutics
CN110637027A (en) 2017-02-08 2019-12-31 百时美施贵宝公司 Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof
CN108623695B (en) * 2017-03-24 2022-03-15 中国科学院过程工程研究所 Albumin binding peptide-human ciliary neurotrophic factor fusion protein and preparation method and application thereof
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US20200181274A1 (en) 2017-06-01 2020-06-11 Novartis Ag Bispecific antibodies that bind cd 123 cd3
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
BR112019025035A2 (en) 2017-06-01 2020-06-30 Compugen Ltd. method to treat cancer
WO2018232406A1 (en) * 2017-06-16 2018-12-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods, systems, and compositions for legume-based production of therapeutic proteins and therapeutic medical materials.
MA49517A (en) 2017-06-30 2020-05-06 Xencor Inc TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND AREAS OF ANTIGEN BINDING
AU2018300069A1 (en) 2017-07-11 2020-02-27 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
US20200181220A1 (en) * 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2019040498A1 (en) * 2017-08-21 2019-02-28 University Of Delaware Peptidic macromolecular assemblies
EP3694535A4 (en) 2017-10-11 2021-07-28 Elanco US Inc. Porcine g-csf variants and their uses
JP2021500930A (en) 2017-11-01 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ COMP Body-Multivalent Target Binding Substance
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
AU2019216759A1 (en) 2018-02-08 2020-08-06 Amgen Inc. Low pH pharmaceutical antibody formulation
CA3091857A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
EP3773910A1 (en) 2018-03-29 2021-02-17 Ambrx, Inc. Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
US20190352362A1 (en) 2018-04-18 2019-11-21 Xencor, Inc. LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112105645A (en) 2018-04-18 2020-12-18 Xencor股份有限公司 IL-15/IL-15RA heterodimer FC fusion protein and application thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3784350A1 (en) 2018-04-27 2021-03-03 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
BR112020022288A2 (en) 2018-05-01 2021-02-23 Ambrx, Inc. method for optimizing the expression of antibodies
EP3802605A1 (en) 2018-06-01 2021-04-14 Compugen Ltd. Anti-pvrig/anti-tigit bispecific antibodies and methods of use
CN112512578A (en) 2018-06-01 2021-03-16 诺华股份有限公司 Administration of bispecific antibodies that bind to CD123 and CD3
CR20210047A (en) 2018-07-02 2021-05-21 Amgen Inc ANTI-STEAP1 ANTIGEN BINDING PROTEIN
TW202019965A (en) 2018-07-16 2020-06-01 美商安進公司 Method of treating multiple myeloma
MA53862A (en) 2018-10-12 2022-01-19 Xencor Inc FC FUSION PROTEINS OF IL-15/IL-15RALPHA TARGETTING PD-1 AND USES IN COMBINATION THERAPIES INVOLVING THE SAME
EP3867265A1 (en) * 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN109439606B (en) * 2018-11-14 2022-06-28 中国科学院青岛生物能源与过程研究所 Genetically engineered bacterium for increasing phloroglucinol yield and construction method and application thereof
JP2022511951A (en) * 2018-12-11 2022-02-01 モレキュラー テクノロジーズ ラボラトリーズ エルエルシー PEGylated growth hormone antagonist
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
CA3127624A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
MX2021009259A (en) 2019-02-06 2021-08-24 Synthorx Inc Il-2 conjugates and methods of use thereof.
JP2022538784A (en) 2019-06-14 2022-09-06 ザ スクリプス リサーチ インスティテュート Reagents and methods for replication, transcription and translation in semi-synthetic organisms
US11857602B2 (en) * 2019-06-17 2024-01-02 Molecular Technologies Laboratories Llc Growth hormone antagonist and anti-cancer composition combination therapy
EP3983002A4 (en) * 2019-06-17 2023-08-02 Molecular Technologies Laboratories LLC Therapeutic pegylated growth hormone antagonists
TW202128757A (en) 2019-10-11 2021-08-01 美商建南德克公司 Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
KR20220083784A (en) * 2019-10-17 2022-06-20 제이씨알 파마 가부시키가이샤 Method for producing a fusion protein of serum albumin and growth hormone
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CA3165460A1 (en) 2020-01-28 2021-08-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
TW202146452A (en) 2020-02-28 2021-12-16 瑞士商諾華公司 Dosing of a bispecific antibody that binds cd123 and cd3
CR20220555A (en) 2020-03-31 2023-01-23 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
CN111938655B (en) * 2020-07-09 2021-09-03 上海交通大学 Orbit soft tissue form evaluation method, system and equipment based on key point information
EP4240765A2 (en) 2020-11-06 2023-09-13 Novartis AG Antibody fc variants
AU2021382599A1 (en) 2020-11-19 2023-06-22 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US11688595B2 (en) 2020-11-20 2023-06-27 Thermo Finnigan Llc Operating a mass spectrometer for sample quantification
JP2023554456A (en) 2020-12-18 2023-12-27 チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド Molecule that specifically binds to respiratory syncytial virus
US20220227867A1 (en) 2020-12-24 2022-07-21 Xencor, Inc. ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
WO2022265109A1 (en) * 2021-06-18 2022-12-22 Peptidream Inc. Ghr-binding pending peptide and composition comprising same
WO2023010031A1 (en) 2021-07-28 2023-02-02 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023015198A1 (en) 2021-08-04 2023-02-09 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
WO2023023283A2 (en) * 2021-08-18 2023-02-23 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
CN114107394B (en) * 2021-11-05 2024-01-30 中国科学院精密测量科学与技术创新研究院 Lentiviral transfer vector, pyleS expression and tRNA CUA Cell line of (C) and preparation method and application thereof
WO2023175498A1 (en) 2022-03-17 2023-09-21 Pfizer Inc. Improved igg-degrading enzymes and methods of use thereof
US20240025968A1 (en) 2022-04-07 2024-01-25 Xencor, Inc. LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
US20230374045A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608183B1 (en) * 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US20050009049A1 (en) * 2003-04-17 2005-01-13 The Scripps Research Institute Expanding the eukaryotic genetic code

Family Cites Families (396)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US85619A (en) * 1869-01-05 Improvement in machine for sowing pulverulent manures
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4241174A (en) 1978-11-24 1980-12-23 Hoffmann-La Roche Inc. Interferon assay
IN150740B (en) 1978-11-24 1982-12-04 Hoffmann La Roche
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US6410697B1 (en) 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5554513A (en) 1979-11-21 1996-09-10 Yeda Research & Development Co. Ltd. Production of recombinant human interferon-beta2
IL58765A (en) 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
ES500966A0 (en) 1980-04-03 1982-12-16 Biogen Nv A METHOD OF PRODUCING A POLYPEPTIDE THAT SHOWS AN OBIOLOGICAL IMMUNOLOGICAL ACTIVITY OF INTERFERON OF HUMAN FIBROBLAST.
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
FR2490675B1 (en) 1980-09-25 1985-11-15 Genentech Inc MICROBIAL PRODUCTION OF HUMAN FIBROPLASTER INTERFERON
WO1982001773A1 (en) 1980-11-07 1982-05-27 Secher David S Assay for interferon
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4364863A (en) 1980-12-29 1982-12-21 Schering Corporation Extraction of interferon from bacteria
WO1982002715A1 (en) 1981-02-04 1982-08-19 Sugano Haruo Human interferon-beta gene
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (en) 1981-04-15 1985-10-25 Sanofi Sa ANTI-CANCER MEDICINAL PRODUCTS CONTAINING THE RICIN-ASSOCIATED CHAIN ASSOCIATED WITH ANTIMELANOMA ANTIBODY AND PROCESS FOR THEIR PREPARATION
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4614651A (en) 1981-07-12 1986-09-30 Damon Biotech, Inc. Interferon epsilon
US4810645A (en) 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
JPS58110600A (en) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd Recombinant plasmid containing human beta-interferon gene
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
US4975276A (en) 1982-01-15 1990-12-04 Cetus Corporation Interferon-alpha 54
US4973479A (en) 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
US5098703A (en) 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
DE3220116A1 (en) 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
IL66733A (en) 1982-09-07 1986-03-31 Yeda Res & Dev Assay for ifn and kit therefor
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4432895A (en) 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5089398A (en) 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
JPS59166086A (en) 1983-03-09 1984-09-19 Teruhiko Beppu Novel development type plasmid and development of vitular prochymosin gene in escherichia coli using it
US4859600A (en) 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4921699A (en) 1983-06-01 1990-05-01 Hoffman-La Roche Inc. Polypeptides having interferon activity
US4816566A (en) 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JP2551746B2 (en) 1983-07-19 1996-11-06 サントリー株式会社 Improved plasmid vector and its use
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4604284A (en) 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
ATE159858T1 (en) 1983-09-26 1997-11-15 Ehrenfeld Udo AGENT AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES OF THE CELLULAR AND HUMORAL IMMUNE DEFENSE
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
FR2556365B1 (en) 1983-12-09 1987-07-31 Transgene Sa INTERFERON-G CLONING AND EXPRESSION VECTORS, TRANSFORMED BACTERIA AND PROCESS FOR PREPARING INTERFERON-G
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
DK518384A (en) 1984-01-31 1985-07-01 Idaho Res Found VECTOR FOR THE MANUFACTURE OF A GENE PRODUCT IN INSECT CELLS, PROCEDURE FOR ITS MANUFACTURING AND ITS USE
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0164556B1 (en) 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
GB8412564D0 (en) 1984-05-17 1984-06-20 Searle & Co Structure and properties
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US4675282A (en) 1984-07-06 1987-06-23 Damon Biotech, Inc. Assay for interferon epsilon
JPS6124599A (en) 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd Novel human interferon-gamma polypeptide derivative
JPS6156199A (en) 1984-08-27 1986-03-20 Shionogi & Co Ltd Novel human interferon alpha
US5120832A (en) 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4963495A (en) 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4665180A (en) 1984-11-06 1987-05-12 Petrolite Corporation Substituted tetrahydropyrimidines and octahydrophenanthridines
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
CA1336076C (en) 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
US5196323A (en) 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
GB8510893D0 (en) * 1985-04-30 1985-06-05 Cpc International Inc Starch separation process
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4636674A (en) * 1985-07-19 1987-01-13 Allied Corporation Linear flux switch alternator
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5516515A (en) 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3683910D1 (en) 1986-09-05 1992-03-26 Cetus Corp OXIDATION RESISTANT MUTEINE FROM BETA-INTERFERON, THEIR PRODUCTION AND THE PREPARATIONS CONTAINING THESE MUTEINE.
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JPS63123383A (en) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp Hybrid promoter, manifestation regulating dna sequence and manifestation vector
US4894330A (en) 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US4908432A (en) 1987-01-09 1990-03-13 New York University Novel polypeptide having gamma-interferon activity
US5190751A (en) 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
EP0349594A4 (en) 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
JP2795850B2 (en) 1987-03-23 1998-09-10 ザイモジェネティクス，インコーポレイティド Yeast expression vector
DE3712564A1 (en) 1987-04-14 1988-11-24 Bioferon Biochem Substanz METHOD FOR THE CONSTRUCTION OF AN ANIMAL CELL LINE FOR THE PRODUCTION OF HUMAN INTERFERON BETA
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5688763A (en) 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
WO1989001038A1 (en) 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
WO1989001037A1 (en) 1987-07-24 1989-02-09 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
IT1222427B (en) 1987-07-31 1990-09-05 Sclavo Spa INTERFERONE PURIFICATION PROCEDURE
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1335792C (en) 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
DE3886880T2 (en) * 1987-10-15 1994-07-14 Syntex Inc Powdery preparations for intranasal administration of polypeptides.
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5192669A (en) 1987-11-09 1993-03-09 Eli Lilly And Company Method to produce recombinant proteins using an expression vector comprising transcriptional and translational activating sequences
US5063158A (en) 1987-11-09 1991-11-05 Eli Lilly And Company Recombinant DNA expression vector comprising both transcriptional and translational activating sequences
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
US5674706A (en) 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
FR2631974B1 (en) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech MODIFIED BACULOVIRUS, ITS PREPARATION METHOD AND ITS APPLICATION AS A GENE EXPRESSION VECTOR
WO1990001556A1 (en) 1988-08-05 1990-02-22 Mount Sinai School Of Medicine Of The City University Of New York In vivo infection of live insects with a recombinant baculovirus
GB8819453D0 (en) 1988-08-16 1988-09-21 Roy P Production of bluetongue virus non-structural proteins using baculovirus expression vector
NZ230425A (en) 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
SE462364B (en) 1988-09-30 1990-06-18 Goeran Hansson USING GAMMA INTERFERON FOR PREPARING A PREPARATION FOR TREATMENT OF VASCULAR STENOS
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
CA2001774C (en) 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
EP0446299A4 (en) 1988-11-18 1992-05-13 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
DE68925966T2 (en) 1988-12-22 1996-08-29 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5268169A (en) 1989-02-02 1993-12-07 Roussel Uclaf Treatment method of ovarian cancer using interferon gamma
WO1990010078A1 (en) 1989-02-23 1990-09-07 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
EP0460071A4 (en) 1989-02-24 1993-02-03 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5196191A (en) 1989-03-17 1993-03-23 Genentech, Inc. Temporal gamma-interferon administration for allergies
IL89662A (en) 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JP2875884B2 (en) 1989-04-19 1999-03-31 ノボ ノルディスク アクティーゼルスカブ Active polyalkylene oxide carbonates for use in modifying polypeptides
WO1990014428A1 (en) 1989-05-17 1990-11-29 University Of Georgia Research Foundation, Inc. Improved baculovirus expression vectors
ATE136315T1 (en) 1989-05-27 1996-04-15 Sumitomo Pharma METHOD FOR THE PRODUCTION OF POLYETHYLENE GLYCOL DERIVATIVES AND MODIFIED PROTEINS.
US5391713A (en) 1989-06-20 1995-02-21 Bionative Ab Interferon purification process
FR2649120B1 (en) 1989-06-30 1994-01-28 Cayla NOVEL STRAIN AND ITS MUTANTS OF FILAMENTOUS MUSHROOMS, PROCESS FOR PRODUCING RECOMBINANT PROTEINS USING SAID STRAIN, AND STRAINS AND PROTEINS OBTAINED BY SAID METHOD
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
AU6643690A (en) 1989-10-23 1991-05-16 Schering Corporation Polypeptide inhibitors of gamma interferon
US5162601A (en) 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US4989830A (en) * 1990-01-26 1991-02-05 Ratnik Industries, Inc. Motorized hydrant
US5849282A (en) 1990-05-09 1998-12-15 Otsuka Pharmaceutical Co., Ltd. Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
PL166045B1 (en) 1990-06-04 1995-03-31 Schering Corp Method of obtaining crystalline alpha-2 interferon
FR2664905B1 (en) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech MODIFIED BACULOVIRUS, PROCESS FOR OBTAINING SAME, AND EXPRESSION VECTORS OBTAINED FROM SAID BACULOVIRUS.
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
JPH06501845A (en) 1990-08-02 1994-03-03 カイロン　コーポレイション Expression of human CMV glycoprotein-H using a baculovirus-insect cell expression system
FR2665923B1 (en) 1990-08-14 1993-01-22 Arbona Jean MODULAR CARE UNIT.
US5594107A (en) 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
JP3051145B2 (en) 1990-08-28 2000-06-12 住友製薬株式会社 Novel polyethylene glycol derivative modified peptide
CA2090969C (en) 1990-09-04 2001-08-21 Russell Arthur Brierley Production of insulin-like growth factor-1 in methylotrophic yeast cells
EP0513332A4 (en) 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
CA2074802A1 (en) 1990-11-29 1992-05-30 Jacques Martal Interferons derived mutants of type i, their production process and applications
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
JPH06506217A (en) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
WO1992016619A1 (en) 1991-03-19 1992-10-01 Us Army Expression of influenza nucleoprotein antigens in baculovirus
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6013433A (en) 1991-04-26 2000-01-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
ATE196548T1 (en) * 1991-05-10 2000-10-15 Genentech Inc SELECTING AGONISTS AND ANTAGONISTS OF LIGANDS
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
DE4128319A1 (en) 1991-08-27 1993-03-04 Bioferon Biochem Substanz NEW RECOMBINANT HUMAN-IFN-BETA, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
KR940006679B1 (en) 1991-09-26 1994-07-25 현대전자산업 주식회사 Dram cell having a vertical transistor and fabricating method thereof
US5863530A (en) 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
US5540923A (en) 1991-12-06 1996-07-30 Landsforeningen Til Kraeftens Bekaemplse Interferon proteins
EP0551535A1 (en) 1992-01-13 1993-07-21 SCLAVO S.p.A. Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them
IT1260468B (en) 1992-01-29 1996-04-09 METHOD FOR MAINTAINING THE ACTIVITY OF PROTEOLYTIC ENZYMES MODIFIED WITH POLYETHYLENGLYCOL
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5591974A (en) 1992-09-30 1997-01-07 Westinghouse Electric Corporation Automated collection and processing of environmental samples
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
EP0678030A1 (en) 1993-01-08 1995-10-25 The Population Council Use of sulphated polysaccharides for preventing sexually transmitted diseases
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5532142A (en) 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
EP0626448A3 (en) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Process for preparing and purifying alpha-interferon
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
WO1994029344A1 (en) 1993-06-11 1994-12-22 Pestka Biomedical Laboratories, Inc. Super proteins including interferons and interleukins
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5491076A (en) 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5711944A (en) 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
FR2715664B1 (en) 1994-01-31 1996-04-12 Proteine Performance Sa Recombinant baculovirus and its use for the production of monoclonal antibodies.
US5624895A (en) 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
JP4001379B2 (en) 1994-03-07 2007-10-31 インペリアル カレッジ オブ サイエンス，テクノロジー アンド メディシン Use of interferon subtypes in the preparation of drugs to treat viral infections
JP3090586B2 (en) 1994-03-15 2000-09-25 片倉工業株式会社 Baculovirus deficient in cysteine protease gene, method for producing the same, and method for producing useful protein using the same
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
WO1995033490A1 (en) 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6403375B1 (en) 1994-08-24 2002-06-11 Boyce Thompson Institute For Plant Research, Inc. Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3467515B2 (en) 1994-11-01 2003-11-17 財団法人ルイ・パストゥール医学研究センター Method for measuring interferon activity
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
CA2223125A1 (en) 1995-02-17 1996-08-22 Stichting Instituut Voor Dierhouderij En Diergezondheid Production of biologically active recombinant bovine follicle stimulating hormone (recbfsh) in the baculovirus expression system
FR2732035B1 (en) 1995-03-23 1997-05-30 Agronomique Inst Nat Rech METHOD FOR REGULATING THE EXPRESSION OF A GENE IN A BACULOVIRUS, BY A FIXATION SITE OF A RETINOIC ACID RECEPTOR, AND VECTOR FOR CARRYING OUT SAID METHOD
JP2758154B2 (en) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
US5770191A (en) 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
WO1996040791A1 (en) 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5780027A (en) 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
DE19535853C2 (en) 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Variants of recombinant human interferon gamma, process for their preparation and their use
ES2338431T3 (en) 1995-09-21 2010-05-07 Genentech, Inc. VARIANTS OF HUMAN GROWTH HORMONE.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5861279A (en) 1996-01-17 1999-01-19 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
AU1690697A (en) 1996-01-17 1997-08-11 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin antagonists
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
EP0904373A1 (en) 1996-03-14 1999-03-31 The Immune Response Corporation Targeted delivery of genes encoding interferon
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US5831062A (en) 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2262994A1 (en) 1996-08-02 1998-02-12 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US5998595A (en) 1996-11-05 1999-12-07 Wako Pure Chemical Industries, Ltd. Azidohalogenobenzyl derivatives, sugar compounds and protection of hydroxy groups
WO1998022129A1 (en) 1996-11-22 1998-05-28 Toray Industries, Inc. Therapeutic agent for ophthalmic diseases
ATE398139T1 (en) 1996-12-13 2008-07-15 Novartis Vaccines & Diagnostic ANALYSIS AND SEPARATION OF PDGF PROTEINS
BR9606270A (en) 1996-12-18 1998-09-22 Univ Minas Gerais Process for the production of recombinant human beta-cis interferon protein and recombinant human beta-cis interferon protein
JP2001508783A (en) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー PEGylation method
US6436391B1 (en) 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
US6118776A (en) 1997-02-18 2000-09-12 Vixel Corporation Methods and apparatus for fiber channel interconnection of private loop devices
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
DE19717864C2 (en) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Human recombinant interferon beta, process for its preparation and its use
JP2002505574A (en) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド Polyalkylene oxide-modified single-chain polypeptides
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
AU744085B2 (en) 1997-06-06 2002-02-14 Kyowa Hakko Kirin Co., Ltd. Chemically modified polypeptides
US5965393A (en) 1997-07-01 1999-10-12 National Institute Of Immunology Method for enhancing foreign gene expression in baculovirus expression vector system
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
WO1999007862A1 (en) 1997-08-05 1999-02-18 Chiron Corporation Novel pichia pastoris gene sequences and methods for their use
DE19735593C2 (en) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Coat protein-modified baculovirus vector for gene therapy
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
AU9393398A (en) 1997-09-16 1999-04-05 Egea Biosciences, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
JP2001517686A (en) 1997-09-26 2001-10-09 ユーエイビー リサーチ ファンデーション Blood cells with reduced antigenicity and uses thereof
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DE19748489A1 (en) 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylene glycol-derivatized biomolecules and their use in heterogeneous detection methods
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ZA9811070B (en) 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
AU761577C (en) 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6225060B1 (en) 1998-03-04 2001-05-01 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
JP4078032B2 (en) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション Poly (ethylene glycol) derivatives with proximal reactive groups
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
KR100264953B1 (en) 1998-04-03 2001-03-02 박현우 Recombinant baculovirus, process for preparing thereof and microbial insecticides containing same
DE69920002T2 (en) 1998-04-28 2005-09-22 Applied Research Systems Ars Holding N.V. CONJUGATES OF POLYOLE AND BETA-INTERFERON
IL139431A0 (en) 1998-05-07 2001-11-25 Transkaryotic Therapies Inc Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AU731758B2 (en) 1998-07-08 2001-04-05 Mitsui Chemicals, Inc. Method for secretory production of human growth hormone
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6245528B1 (en) 1998-07-28 2001-06-12 Academia Sinica Latent baculovirus expression system
US6368825B1 (en) 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter
AU764144B2 (en) 1998-08-28 2003-08-14 Gryphon Therapeutics, Inc. Polyamide chains of precise length, methods to manufacture them and their conjugates
IL142061A0 (en) 1998-09-18 2002-03-10 Zymogenetics Inc Interferon-epsilon
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PT1121382E (en) 1998-10-16 2006-10-31 Biogen Idec Inc BETA INTERFERENCE FUSE PROTEINS AND THEIR RESPECTIVE USES
PT1121156E (en) * 1998-10-16 2006-05-31 Biogen Idec Inc CONJUGATES OF INTERFERRO-BETA-1A POLYMERS AND THEIR USES
WO2000026354A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
ES2226326T3 (en) * 1998-12-17 2005-03-16 Applied Research Systems Ars Holding N.V. HUMAN GROWTH HORMONE TO STIMULATE HEMATOPOYESIS AND RECONSTITUTION OF THE IMMUNE SYSTEM AFTER HEMATOPOYETIC MOTHER CELL TRANSPLANTATION IN HUMAN BEINGS.
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
JP4805432B2 (en) 1998-12-28 2011-11-02 ランクセス・ドイチュランド・ゲーエムベーハー Chemicals for admixing adhesives used in manufacturing wood materials or wood composite materials
US6350589B1 (en) 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US6433144B1 (en) 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US6703225B1 (en) 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6342216B1 (en) 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
EP1177311B1 (en) 1999-03-17 2014-11-12 The Board Of Trustees Of The Leland Stanford Junior University In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
DE60026983T2 (en) 1999-04-16 2007-01-25 William Marsh Rice University, Houston FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE COETHYLENE GLYCOL
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
EP1187852B1 (en) 1999-05-19 2007-08-08 EMD Lexigen Research Center Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US6270756B1 (en) 1999-08-30 2001-08-07 Rx/Ibr Corporation Weight loss induced by alpha interferon and gamma interferon
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
PT1259563E (en) 1999-12-22 2009-04-14 Nektar Therapeutics Al Corp Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.
WO2001046291A1 (en) 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
EP1272624A4 (en) 2000-03-16 2004-06-16 Shantha Biotechnics P Ltd A process for the production of human interferon alpha from genetically engineered yeast
NZ522030A (en) * 2000-05-15 2004-11-26 F Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition
GB0012997D0 (en) 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
JP2002030098A (en) 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd Method for recovering virion envelope from budded virus of baculovirus
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
AU2002212107A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
KR100401296B1 (en) * 2000-12-27 2003-10-11 드림바이오젠 주식회사 Protein Muteins Modified By Modifying Materials And Method For Producing The Same
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
DE60226411D1 (en) 2001-01-25 2008-06-19 Anthony C Forster METHOD AND COMPOSITIONS FOR PEPTIDE, PROTEIN AND PEPTIDOMIMETIC SYNTHESIS
US7045337B2 (en) * 2001-04-19 2006-05-16 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US6566132B1 (en) 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
US7232563B2 (en) 2001-08-12 2007-06-19 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
CA2459138A1 (en) * 2001-09-04 2003-03-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified human growth hormone
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2556338T3 (en) * 2001-10-10 2016-01-15 Novo Nordisk A/S Remodeling and glycoconjugation of peptides
MXPA04004336A (en) 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Branched polymers and their conjugates.
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
DE60332725D1 (en) 2002-05-30 2010-07-08 Scripps Research Inst COPPER-CATALYZED LEADING OF AZIDES AND ACETYLENES
AU2003253781A1 (en) 2002-07-03 2004-01-23 University Of Central Florida Expression of human interferon in transgenic chloroplasts
CA2497777A1 (en) 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
KR20050072441A (en) 2002-10-16 2005-07-11 더 스크립스 리서치 인스티튜트 Site specific incorporation of keto amino acids into proteins
KR20050073559A (en) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 Glycoprotein synthesis
MXPA05005178A (en) 2002-11-15 2005-07-22 Hoffmann La Roche Positional isomers of peg ifn alpha 2a.
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1583816A4 (en) 2002-12-22 2007-06-13 Scripps Research Inst Protein arrays
BRPI0411475A (en) 2003-06-18 2006-07-25 Scripps Research Inst unnatural reactive amino acid genetic code additions
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
EP1649004A4 (en) 2003-07-07 2008-04-09 Scripps Research Inst Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
EP1675620B1 (en) 2003-10-09 2019-05-08 Ambrx, Inc. Polymer derivatives
WO2005074524A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human interferon polypeptides and their uses
AU2005319099B2 (en) * 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
US20060040076A1 (en) * 2004-08-18 2006-02-23 Franzyshen Stephen K Formable film for cold-form, blister-type pharmaceutical packaging
NZ620606A (en) * 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608183B1 (en) * 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US20050009049A1 (en) * 2003-04-17 2005-01-13 The Scripps Research Institute Expanding the eukaryotic genetic code

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9175083B2 (en) 2004-06-18 2015-11-03 Ambrx, Inc. Antigen-binding polypeptides and their uses
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Also Published As

Publication number Publication date
JP2007519422A (en) 2007-07-19
MXPA06008507A (en) 2008-02-13
ATE546463T1 (en) 2012-03-15
BRPI0507159A (en) 2007-06-26
AU2005211362A1 (en) 2005-08-18
IL176595A (en) 2014-12-31
CN103755800A (en) 2014-04-30
US20050170404A1 (en) 2005-08-04
US20080097083A1 (en) 2008-04-24
AU2009200832B2 (en) 2012-05-10
US20080108791A1 (en) 2008-05-08
EP2327724A3 (en) 2011-07-27
GB2429207A9 (en) 2007-03-05
US20080300163A1 (en) 2008-12-04
KR20060130181A (en) 2006-12-18
US8906676B2 (en) 2014-12-09
US8232371B2 (en) 2012-07-31
EP1718339A2 (en) 2006-11-08
CA2553034A1 (en) 2005-08-18
US8907064B2 (en) 2014-12-09
GB0617302D0 (en) 2006-10-18
GB2429207A (en) 2007-02-21
AU2011202106A1 (en) 2011-05-26
MXPA06008506A (en) 2007-01-30
EP1740608A4 (en) 2008-09-03
EP2327724A2 (en) 2011-06-01
US20120142896A1 (en) 2012-06-07
BRPI0507118A (en) 2007-06-19
GB2426521A (en) 2006-11-29
US9260472B2 (en) 2016-02-16
KR20060130182A (en) 2006-12-18
EP1740608A2 (en) 2007-01-10
JP4896745B2 (en) 2012-03-14
IL176596A0 (en) 2008-04-13
CN103755800B (en) 2016-02-24
GB0617304D0 (en) 2006-10-25
CA2553040A1 (en) 2005-08-18
WO2005074524A2 (en) 2005-08-18
NZ586034A (en) 2011-10-28
US20050220762A1 (en) 2005-10-06
US20080146781A1 (en) 2008-06-19
AU2009200832A1 (en) 2009-03-19
GB0617303D0 (en) 2006-10-18
EP1718664A2 (en) 2006-11-08
US20080103294A1 (en) 2008-05-01
US20140296145A1 (en) 2014-10-02
AU2005211362B2 (en) 2008-03-13
WO2005074546A3 (en) 2007-01-04
US20080161539A1 (en) 2008-07-03
NZ548256A (en) 2010-02-26
CA2553035A1 (en) 2005-08-18
AU2005209926A1 (en) 2005-08-18
AU2005211385A1 (en) 2005-08-18
EP1718339A4 (en) 2008-08-13
IL176594A0 (en) 2008-04-13
KR20070007086A (en) 2007-01-12
AU2011202106B2 (en) 2012-09-13
AU2005211385B2 (en) 2008-12-11
JP4889505B2 (en) 2012-03-07
SG135176A1 (en) 2007-09-28
MXPA06008496A (en) 2007-01-30
BRPI0507169A (en) 2007-06-26
US8778880B2 (en) 2014-07-15
NZ548255A (en) 2010-10-29
US8097702B2 (en) 2012-01-17
US20080114155A1 (en) 2008-05-15
GB2429207A8 (en) 2007-03-05
HK1099776A1 (en) 2007-08-24
AU2005209926B2 (en) 2007-09-06
US20080103293A1 (en) 2008-05-01
EP1740608B1 (en) 2012-02-22
IL176595A0 (en) 2008-04-13
WO2005074650A3 (en) 2006-09-28
WO2005074546A2 (en) 2005-08-18
US20080207877A1 (en) 2008-08-28
EP1718664A4 (en) 2008-08-13
GB2426762A (en) 2006-12-06
WO2005074650A2 (en) 2005-08-18
US20080114154A1 (en) 2008-05-15
JP2007519420A (en) 2007-07-19
NZ548257A (en) 2011-02-25
US20080108797A1 (en) 2008-05-08
US8119603B2 (en) 2012-02-21
KR101207123B1 (en) 2012-12-04
JP2007520223A (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2005074524A3 (en) Modified human interferon polypeptides and their uses
WO2006133089A3 (en) Improved human interferon molecules and their uses
WO2006069220A3 (en) Modified human growth hormone
IL179300A0 (en) Novel-antigen-binding polypeptides and their uses
EP1824796A4 (en) Protein scaffolds and uses thereof
EP1799840A4 (en) Ilt3 polypeptides and uses thereof
EP1652855A4 (en) Polypeptides having brain -localizing activity and uses thereof
ZA200606216B (en) Modified human interferon polypeptides and their uses
EP1824978A4 (en) Hcv f protein and uses thereof
EP1829969A4 (en) Novel polypeptide and the use thereof
GB0309064D0 (en) Modified peptides and their uses
EP1813671A4 (en) Soluble protein and utilization of the same
ZA200609926B (en) Novel antigen-binding polypeptides and their uses
EP1735334A4 (en) Set1 proteins and uses therefor
GB0401303D0 (en) Polypeptide and uses thereof
AU2003263751A1 (en) Novel proteins and their uses
AU2004900719A0 (en) Sperm-Active Preparations and Uses Thereof
GB0425731D0 (en) Isolated peptides and uses thereof
AU2004901814A0 (en) Recombinant Mannoproteins and Uses Thereof
AU2004905339A0 (en) Protein fragments and uses thereof
AU2004901570A0 (en) Set1 proteins and uses therefor
GB0419677D0 (en) Novel polypeptides, antibodies thereto and uses thereof
AU2004901114A0 (en) Recombinant perforin, expression and uses thereof
AU2005905904A0 (en) Leukocyte-binding polypeptides and uses thereof
GB0321401D0 (en) Antibodies,polypeptides and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 176596

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005211362

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 548255

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2553034

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2005211362

Country of ref document: AU

Date of ref document: 20050128

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005211362

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/06216

Country of ref document: ZA

Ref document number: PA/a/2006/008496

Country of ref document: MX

Ref document number: 200606216

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2006551473

Country of ref document: JP

Ref document number: 200580003787.6

Country of ref document: CN

Ref document number: 2818/CHENP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 1020067016851

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2005712158

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 0617303.3

Country of ref document: GB

Ref document number: 0617303

Country of ref document: GB

WWP Wipo information: published in national office

Ref document number: 2005712158

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067016851

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0507118

Country of ref document: BR